According to the WHO, one adult in six globally is affected by infertility, but beyond this statistic, infertility is best understood as a couple’s problem, even when the underlying biology sits with one partner. The way we currently handle infertility issues is more about bypassing biology through procedure, with in vitro fertilisation (IVF) as its backbone. But while IVF is indispensable, success rates still vary, pushing biotech to step in and find new solutions.
Can biotech finally fix infertility?
Background, Latest NewsAccording to the WHO, one adult in six globally is affected by infertility, but beyond this statistic, infertility is best understood as a couple’s problem, even when the underlying biology sits with one partner. The way we currently handle infertility issues is more about bypassing biology through procedure, with in vitro fertilisation (IVF) as its backbone. But while IVF is indispensable, success rates still vary, pushing biotech to step in and find new solutions.
Roche’s fenebrutinib cuts relapses in MS amid safety concerns
Latest NewsSwiss pharma giant Roche announced that its investigational BTK inhibitor fenebrutinib sharply reduced multiple sclerosis relapses in Phase III studies. However, death imbalances cloud the picture.
UCB spends US$1.15bn on cell therapy biotech for potential regenerative epilepsy therapy
Latest NewsBelgian biopharma UCB has agreed to acquire clinical-stage biotech Neurona Therapeutics for up to US$1.15 billion, betting on a one-off cell therapy that aims to structurally repair the brains of people with drug-resistant epilepsy.
Next stage of growth with a new CEO
AppointmentsDr Deborah Jones joined the Dutch Resyca BV as CEO at the beginning of April, succeeding Remko Beimers, who has stepped down from his role.
Proteins.1 launches with €4.7m to make protein detection as easy as PCR
Latest NewsA newly launched Finnish deep-tech company has cracked the code for single-molecule protein detection. VTT-originated Proteins.1 has launched with €4.7m in pre-seed funding, aiming to stop the deadliest diseases before symptoms even appear.
Spain plants US$200m flag in Boston with debut US biotech fund
Latest NewsSpain has launched a US$200m venture capital fund anchored in Boston to help Spanish biotech companies scale in one of the world’s foremost life sciences ecosystem. The initiative includes a new trade office in Massachusetts and around US$57m in public seed capital.
Novo Nordisk is going all in on AI
Latest NewsNovo Nordisk becomes the latest major pharma player to trust the future of its drug discovery to AI. However, the Danish pharma heavyweight is going one step further: The partnership with Open AI is set to embed advanced artificial intelligence across everything from early R&D to commercial operations.
Can Europe finance and keep its biotech winners?
Latest News, OpinionThe recent resurgence of life sciences IPOs in the US highlights a persistent structural imbalance: Europe generates world-class science but struggles to finance and retain it. The European Life Sciences Coalition was created to address this gap by mobilizing institutional capital and strengthening the policy framework needed to scale European innovation at home.
Europe’s distinct biotech venture studio model
Background, Latest NewsFor decades, biotech companies were formed around a discovery: a promising biological signal, a novel target, a platform emerging from academic research. Now a different formation model is gaining momentum: venture studios. These entities don’t just fund startups, they assemble them, testing hypotheses, building teams and infrastructure, and only then spinning out companies designed to scale.
Adcendo banks US$75m to push ADC pipeline forward
Latest NewsCopenhagen-based biotech Adcendo ApS has closed an oversubscribed US$75 million Series C round led by Jeito Capital. The funds will fuel early-phase trials of three ADC candidates for cancers with high unmet need.